Compare Funko Inc (FNKO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Natera Inc. Common Stock — how do they compare? Funko Inc trades at $6.31 (market cap $365.09M), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 156.2× Funko Inc's market cap, and Funko Inc is more actively traded (435,098 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Natera Inc. Common Stock for 0 Days on average.
| FNKO | NTRA | |
|---|---|---|
Market Cap | $365.09M | $57.03B |
Volume | 435,098 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $425.64 |
52-Week Low | $2.81 | $179.42 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $585.74M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.35, down 1.7% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving fundamentals with Q2 2026 earnings beating expectations, revenue growth of 7% year-over-year, and raised EBITDA guidance to $105 million. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 19% upside potential from current levels.
Investment outlook remains cautiously optimistic as FNKO demonstrates operational improvements with margin expansion and debt reduction. Key risks include negative net income margins, volatile cash flow patterns, and competitive pressures in the collectibles market. The stock offers value with a low P/S ratio of 0.39x and attractive EV/EBITDA of 6.84x, but requires sustained profitability to justify further appreciation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
